Redeye shares its initial take on Genovis following the Q1 report, which delivered sales 13% above our estimates and an EBITDA margin of 28%, in line with our expectations. Enzyme sales reached their highest level to date, excluding license-related revenues while the share continue to trade at a slight premium to our bear case.
LÄS MER
